What a privilege it was for Lara and I to present Calla Lily Clinical Care to senior members of Merck Group and M Ventures . Selected out of 100+ women’s health startups from around the world, we were able to share our vision for our transformational Callavid drug delivery platform, beginning with pregnancy & fertility. 🌸

Engaging and learning from Merck Healthcare’s global fertility and business development leaders was such a valuable experience. As any founder will attest to, there’s no end to opinions (and noise) out there about strategy, and particularly those who question why we have chosen to initially focus on the delivery of “simple” progesterone. I came away from such helpful and rewarding dialogue more resolutely focused than ever that we’re on the right path. 📈

Thank you to the 8 Merck “dragons” for the insightful feedback and rich engagement, and special thanks to Nathan and the SiS: Women’s Health team for facilitating such a fantastic event. 🙏